# A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer

Source: https://onco.cc/trials/nct05257395/  
OnCo record `nct05257395` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of XZP-3287 in advanced solid tumours, run by Xuanzhu Biopharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer is a phase 3 interventional study registered as NCT05257395 by Xuanzhu Biopharmaceutical Co., Ltd., with 397 participants enrolled, started 2022-03-14 and due to reach its primary completion in 2025-12-05. Interventions recorded: XZP-3287+ Letrozole/Anastrozole and Placebo + Letrozole/Anastrozole.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05257395
- Phase: 3
- Setting: A Phase III Study to Evaluate the Efficacy and Safety of XZP-3287 Combined With Letrozole/Anastrozole Versus Placebo Combined With Letrozole/Anastrozole in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer
- Sponsor: Xuanzhu Biopharmaceutical Co., Ltd.
- Enrolled: 397

## Sources

- ClinicalTrials.gov NCT05257395: https://clinicaltrials.gov/study/NCT05257395

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [XZP-3287](https://onco.cc/drugs/xzp-3287/)
- companies: [Xuanzhu Biopharmaceutical](https://onco.cc/companies/xuanzhu-biopharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct05257395.json